Indication
Cancer Recurrence
5 clinical trials
5 products
Product
Bacillus Calmette-GuerinClinical trial
A Multicenter, Randomized, Double-blind, Controlled Phase III Non-inferiority Study Assessing Efficacy and Safety of VERITY-BCG in Management of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) in BCG-naïve Patients.Status: Not yet recruiting, Estimated PCD: 2025-12-30
Product
RheniumClinical trial
Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior ChemotherapyStatus: Recruiting, Estimated PCD: 2009-06-20
Product
PG2Clinical trial
PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced MalignancyStatus: Completed, Estimated PCD: 2003-10-01
Clinical trial
Multicentre Clinical Trial of the Efficacy and Safety of Tislelizumab in Combination With BCG Bladder Instillation in the Prevention of Postoperative Recurrence in Intermediate and High-risk Non-muscle Invasive Bladder CancerStatus: Recruiting, Estimated PCD: 2025-06-01
Product
TislelizumabClinical trial
Does Directly Acting Antivirals Usage Affect HCV Related Hepatocellular Carcinoma Recurrence After Percutaneous Ablation: A Randomized Controlled TrialStatus: Completed, Estimated PCD: 2022-10-24
Product
Velpatasvir/Sofosbuvir